Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.

A Sarnaik, HM Kluger, JA Chesney, J Sethuraman… - 2017 - ascopubs.org
3045 Background: Adoptive cell therapy with TIL involves collection of autologous
lymphocytes from the tumor via surgical resection, ex vivo expansion of TIL …

Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future

A Betof Warner, PG Corrie, O Hamid - Clinical Cancer Research, 2023 - AACR
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is gaining momentum and
demonstrating durable responses in patients with advanced melanoma. Although …

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2

LT Nguyen, SD Saibil, V Sotov, MX Le, L Khoja… - Cancer Immunology …, 2019 - Springer
Adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TIL) has shown
significant clinical benefit, but is limited by toxicities due to a requirement for post-infusion …

[HTML][HTML] Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma

MW Rohaan, TH Borch, JH Van Den Berg… - New England journal …, 2022 - Mass Medical Soc
Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …

Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome

MA Forget, C Haymaker, KR Hess, YJ Meng… - Clinical Cancer …, 2018 - AACR
Purpose: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has
consistently demonstrated clinical efficacy in metastatic melanoma. Recent widespread use …

Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma

JE Mullinax, ML Hall, S Prabhakaran, J Weber… - Frontiers in …, 2018 - frontiersin.org
Purpose Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic
melanoma can be highly effective, but attrition due to progression before TIL administration …

Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response

MJ Besser, O Itzhaki, G Ben‐Betzalel… - Molecular …, 2020 - Wiley Online Library
Adoptive cell transfer (ACT) of tumor‐infiltrating lymphocytes (TIL) mediates objective
responses in 30% to 50% of patients with metastatic melanoma according to multiple, small …

Tumor-infiltrating lymphocytes: clinical experience

MJ Besser, R Shapira-Frommer… - The Cancer Journal, 2015 - journals.lww.com
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with
lymphodepletion and high-dose interleukin 2 has shown reproducible objective response …

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option

MW Rohaan, JH van den Berg, P Kvistborg… - … for immunotherapy of …, 2018 - Springer
The treatment of metastatic melanoma patients with autologous tumor-infiltrating
lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in …

Adoptive cell therapy with tumor‐infiltrating lymphocytes in advanced melanoma patients

M Saint-Jean, AC Knol, C Volteau… - Journal of …, 2018 - Wiley Online Library
Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor‐
infiltrating lymphocytes (TILs). This monocenter retrospective study was undertaken to …